<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04462263</url>
  </required_header>
  <id_info>
    <org_study_id>HTL0014242-103</org_study_id>
    <secondary_id>2020-000602-28</secondary_id>
    <secondary_id>247490</secondary_id>
    <nct_id>NCT04462263</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects</brief_title>
  <official_title>An Open-label, Single Centre, Single Oral Dose Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heptares Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heptares Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study in Healthy Volunteers to Investigate How a New Drug for the Treatment of Parkinson's&#xD;
      Disease, Dystonia and Amyotrophic Lateral Sclerosis Binds to Receptor Sites in the Brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single dose, adaptive study of orally adminstered HTL0014242 in up to&#xD;
      10 healthy male subjects. The primary objective is to investigate the&#xD;
      pharmacokinetic-receptor occupancy relationship of single oral doses of HTL0014242 in healthy&#xD;
      subjects. The secondary objectives are to assess the plasma pharmacokinetics (PK), safety and&#xD;
      tolerability of single oral doses of HTL0014242 in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Actual">June 23, 2021</completion_date>
  <primary_completion_date type="Actual">June 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Receptor Occupancy Endpoint</measure>
    <time_frame>Day 1 post-dose timepoint</time_frame>
    <description>The regional brain Receptor Occupancy profile of HTL0014242, measured by Positron Emission Tomography (PET) imaging with[18F]FPEB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Receptor Occupancy Endpoint</measure>
    <time_frame>Day 2 post-dose timepoint</time_frame>
    <description>The regional brain Receptor Occupancy profile of HTL0014242, measured by Positron Emission Tomography (PET) imaging with[18F]FPEB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum plasma concentration</measure>
    <time_frame>Baseline up to 14(+3) days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma-concentration curve</measure>
    <time_frame>Baseline up to 14(+3) days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum plasma concentration (Tmax) of HTL0014242</measure>
    <time_frame>Baseline up to 14(+3) days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of HTL0014242</measure>
    <time_frame>Baseline up to 14(+3) days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total plasma clearance (CL/F)</measure>
    <time_frame>Baseline up to 14(+3) days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to 14(+3) days post dose</time_frame>
    <description>Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single Dose HTL0014242</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study consists of up to 5 dosing groups, with 2 to 3 subjects per dosing group. Each subject will receive a single oral dose of HTL0014242 in the form of solid suspension capsules (1, 5, 10, and 30mg) as required. HTL0014242 will be administered in up to 5 single dose groups, with 120mg administered in the first dosing group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0014242</intervention_name>
    <description>Solid suspension capsule</description>
    <arm_group_label>Single Dose HTL0014242</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male, aged between 23 and 55 years inclusive, with body mass index between&#xD;
             18.5 and 32 kg/m2.&#xD;
&#xD;
          -  Healthy on the basis of a clinical history, physical examination, electrocardiogram&#xD;
             (ECG), vital signs and laboratory tests of blood and urine.&#xD;
&#xD;
          -  Able to give fully informed consent and has suitable veins for cannulation and&#xD;
             arterial access in both wrists&#xD;
&#xD;
          -  Resting BP and heart rate within normal ranges after 5 mins rest.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past, current or family history of mental, behavioural or neurodevelopmental disorder.&#xD;
&#xD;
          -  Clinically significant history or evidence of cardiovascular, respiratory, hepatic,&#xD;
             renal, gastrointestinal, endocrine, neurological, immunological, pyschiatric&#xD;
             disorders, metabolic, allergic, dermatological, haematological, pulmonary or&#xD;
             respiratory disorder.&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance or allergy to any drug compound,&#xD;
             food or other substance, unless approved by Investigator.&#xD;
&#xD;
          -  Active neoplastic disease or history of any neoplastic disease within 5 years of&#xD;
             screening.&#xD;
&#xD;
          -  Active infection (e.g sepsis, pneumonia, abscess) or serious infection (e.g resulting&#xD;
             in hospitalisation or requiring parenteral antibiotic treatment) within 90 days prior&#xD;
             to dosing.&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection.&#xD;
&#xD;
          -  Any of following at screening or pre-dose: QT internal heart rate correction; QRS&#xD;
             duration &gt;120ms; PR interval &gt; 220ms; QTc measurements/data difficult or&#xD;
             uninterpreable; history of additional risk factors for torsades de pointe.&#xD;
&#xD;
          -  drug or alcohol abuse in last 2 years.&#xD;
&#xD;
          -  Alcohol consumption is &gt; 14 units per week&#xD;
&#xD;
          -  Positive Urine alcohol or drug tests&#xD;
&#xD;
          -  Positive HIV, Hep B, Hep C test&#xD;
&#xD;
          -  Aspartate aminotransferase, Alanine aminotransferase, Gamma glutamyl transferase,&#xD;
             Alkaline phosphatase or total bilirubin above normal upper limits&#xD;
&#xD;
          -  Participation in other clinical trials of unlicensed medicines in the previous 3&#xD;
             months, or 7 half-lives of the medicine (whichever is longer)&#xD;
&#xD;
          -  Previously dosed with HTL0014242.&#xD;
&#xD;
          -  Intention to use or using medications that interfere with drug absorption, metabolism&#xD;
             or elimination processes incl St John's Wort, 30 days prior to dosing.&#xD;
&#xD;
          -  Use of ketamine, amphetamines or MDMA with 9o days prior to dosing&#xD;
&#xD;
          -  Use or intend to use any prescription or non-prescription medications within 14 days&#xD;
             or 5 half-lives of medication, prior to dosing. Investigator and study team to&#xD;
             determine implications on safety or study procedures, on a case-by-case basis.&#xD;
&#xD;
          -  Received live attenuated vaccination within 6 weeks prior to Screening, or intends to&#xD;
             receive vaccination during the study.&#xD;
&#xD;
          -  Smoker or user of tobacco- or nicotine-containing products.&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to dosing. Donation of blood /&#xD;
             comparable blood loss 3 months prior to dosing.&#xD;
&#xD;
          -  Abnormal Allen's circulation test result. Evaluation of arterial access indicates risk&#xD;
             of occlusion or insufficient supply. Evaluation of venous access indicates&#xD;
             difficulties in obtaining venous blood.&#xD;
&#xD;
          -  Subject unable or unwilling to abstain from alcohol or caffeine-containing foods and&#xD;
             beverages. Significant consumption of any foods or beverages containing CYP1A2&#xD;
             inducers with 2 weeks prior to Admission (Investigator opinion).&#xD;
&#xD;
          -  Significant consumption of any foods or beverages containing Seville-type oranges,&#xD;
             grapefruit, or poppy seeds within 7 days prior to baseline PET and admission&#xD;
             (Investigator opinion).&#xD;
&#xD;
          -  Subject, in opinion of Investigator should not participate in this study. Reply from&#xD;
             GP, for this specific study probing psychiatric history must be received before&#xD;
             dosing.&#xD;
&#xD;
          -  Participation in research study or other radiation exposure (e.g workplace) which in&#xD;
             conjunction with this study will exceed ionisation radiation exposure over 10mSv&#xD;
             within 12 months prior to the Screening visit.&#xD;
&#xD;
          -  Contraindication for MRI, assessed by standard pre-MRI questionnaire, that preclude&#xD;
             subject undergoing MRI scans.&#xD;
&#xD;
          -  Subject suffers from claustrophobia (incapable of undergoing MRI or PET scan) or&#xD;
             needle phobia.&#xD;
&#xD;
          -  Subject has abnormal findings per structural MRI scan at screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parexel Early Phase Clinical Unit</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single dose</keyword>
  <keyword>Open-label</keyword>
  <keyword>Oral</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

